Ethical stem cell source program gaining momentum
RANCHO CORDOVA, Calif., October 11, 2001 (LSN.ca) – ThermoGenesis Corp. (Nasdaq: KOOL), a company which specializes in materials for cryopreservation of blood components, announced yesterday that it had received a fifth order for their BioArchive System from the New York Blood Center (“NYBC”). The release explained that NYBC’s Placental Blood Program has pioneered the use of Placental Cord Blood (“PCB”) as a source of stem cells for bone marrow restoration for such diseases as leukemia or inherited or acquired diseases of the blood and immune systems.
Philip Coelho, CEO of ThermoGenesis Corp said, “With the recent bio-ethical issues raised regarding embryonic stem cell research, cord blood may provide a source of stem cells for tissue regeneration without the ethical issues involved with embryos or fetuses. We believe our BioArchive Systems position us well in the growing cell therapy market.” The release noted that BioArchive Systems have also been chosen by the major cord blood banks in Japan, China, Taiwan, Vietnam, So. Korea, Malaysia, Germany, Spain, Finland, U.K., Belgium, France, Mexico, India, and Israel as well as in the U.S.A.
See the company’s press release: https://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-10-2001/0001588586&EDATE=